Video

The Pharmacist’s Role in Understanding Adverse Drug Events

Calvin Knowlton, BSc Pharm, MDiv, PhD, and CEO, Chairman, & Founder of Tabula Rasa Healthcare, discusses how pharmacists should approach adverse drug events and reactions to better help their patients.

Calvin Knowlton, BSc Pharm, MDiv, PhD, and CEO, Chairman, & Founder of Tabula Rasa Healthcare, discusses how pharmacists should approach adverse drug events and reactions to better help their patients. This video was filmed at the 2019 NCPA Annual Convention in San Diego.

Calvin Knowlton, BSc Pharm, MDiv, PhD: The issue with side effects that lead to adverse drug events frequently, is that they’re invisible to the pharmacist because the system that we have been using for almost 50 years only shows us the interaction of 1 drug to 1 drug. And it just tells us from the literature, that when you take these 2 drugs, this may happen. It’s very binary. You’re supposed to flip a coin and say, 'ok stop this one or stop that one.' If you have somebody on 10 meds, you’re supposed to do this drug against these 9, this drug against these 9, this drug—you know. And it just leads to alert fatigue, and it still doesn’t tell you anything because it’s just telling you what’s been reported in the literature.

So, what we’ve done is look at a more mechanistic approach. We say ok—we conceptualized it back in 2011 as a bicycle wheel with spokes going into a hub, and drugs around the outside. And said 'let’s build a hub, software, that can tell the pharmacist exactly what’s under the hood for these 10 drugs or any 10 drugs.' You know, what are the pharmacokinetics that are there, what are the pharmacodynamics, what are the pharmacogenomics—all the science that pharmacists learned in school. And we put that there so that they can then identify risk.

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Cavan - stock.adobe.com
Image Credit: © utah51 - stock.adobe.com
Image Credit: © Rawpixel.com - stock.adobe.com